Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

May 25, 2021 updated by: Theracos

A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin Versus Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin

The purpose of this study is to investigate the effect of bexagliflozin compared to glimepiride as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Approximately 420 subjects with inadequately controlled T2DM on metformin will be recruited from North America and Europe. Subjects will be randomly assigned to receive bexagliflozin tablets, 20 mg, or glimepiride capsules, 2, 4 or 6 mg, in a ratio of 1:1 once daily for 96 weeks. Subjects will continue to take metformin for the duration of the study.

Study Type

Interventional

Enrollment (Actual)

426

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
      • Aschaffenburg, Germany, 63739
        • Research Site
      • Essen, Germany, 45277
        • Research Site
      • Essen, Germany, 45355
        • Research Site 2
      • Hamburg, Germany, 22607
        • Research Site
      • Hamburg, Germany, 21073
        • Research Site 2
      • Heidelberg, Germany, 69115
        • Research Site
      • Magdeburg, Germany, 39120
        • Research Site
      • Wangen, Germany, 88239
        • Research Site
  • Poland
      • Bochnia, Poland, 32-700
        • Research Site
      • Bydgoszcz, Poland, 85-312
        • Research Site
      • Kraków, Poland, 30-015
        • Research Site
      • Kraków, Poland, 31-011
        • Research Site 2
      • Lublin, Poland, 20-362
        • Research Site
      • Lublin, Poland, 20-064
        • Research Site 2
      • Olsztyn, Poland, 10-117
        • Research Site
      • Poznań, Poland, 61-655
        • Research Site
      • Puławy, Poland, 24-100
        • Research Site
      • Staszów, Poland, 28-200
        • Research Site
      • Swarzędz, Poland, 62-020
        • Research Site
      • Toruń, Poland, 87-100
        • Research Site
      • Warszawa, Poland, 00-660
        • Research Site
      • Zamość, Poland, 22-400
        • Research Site
      • Łódź, Poland, 90-242
        • Research Site
      • Świdnik, Poland, 21-040
        • Research Site
  • Spain
      • Alicante, Spain
        • Research Site
      • Barcelona, Spain
        • Research Site
      • Barcelona, Spain
        • Research Site 2
      • Madrid, Spain
        • Research Site
      • Madrid, Spain
        • Research Site 2
      • Madrid, Spain
        • Research Site 3
      • Malaga, Spain
        • Research Site
      • Malaga, Spain
        • Research Site 2
      • Oviedo, Spain
        • Research Site 2
      • Valencia, Spain
        • Research Site
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35205
        • Research Site
    • California
      • Huntington Park, California, United States, 90255
        • Research Site
      • Los Angeles, California, United States, 90057
        • Research Site
      • San Carlos, California, United States, 94070
        • Research Site
    • Florida
      • Hialeah, Florida, United States, 33012
        • Research Site
      • Miami Lakes, Florida, United States, 33016
        • Research Site
      • Orlando, Florida, United States, 32806
        • Research Site
      • West Palm Beach, Florida, United States, 33401
        • Research Site
    • North Carolina
      • Calabash, North Carolina, United States, 28467
        • Research Site
      • Morehead City, North Carolina, United States, 28557
        • Research Site
    • Texas
      • Magnolia, Texas, United States, 77355
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of T2DM
  • Currently taking metformin or taking metformin and one additional oral medication for diabetes
  • Body Mass Index (BMI) ≤ 45 kg/m2
  • Stable dose of blood pressure or cholesterol medications (if applicable) for at least 30 days

Exclusion Criteria:

  • Hypersensitivity or other contraindication to the safe use of sulfonylurea or glimepiride
  • Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young
  • Current use of injected therapy for treatment of diabetes (insulin or GLP-1 receptor agonist therapy) or thiazolidinedione class drugs
  • History of genitourinary tract infections
  • Evidence of abnormal liver function
  • Myocardial infarction, stroke or hospitalization for heart failure within 3 months of screening
  • Prior kidney transplant or evidence of kidney problems
  • Pregnant or nursing

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Bexagliflozin
Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for glimepiride daily for the duration of the study.
Drug: Bexagliflozin
20 mg, tablet
Other Names:
  • EGT0001442
Drug: Placebo for Glimepiride
inactive capsules to match active comparator glimepiride
Active Comparator: Glimepiride
Subjects will receive a glimepiride capsule, 2, 4 or 6 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
Drug: Placebo for Bexagliflozin
inactive tablet to match active comparator bexagliflozin
Drug: Glimepiride
2, 4 or 6 mg, capsule

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in HbA1c at Week 60
Time Frame: Baseline and Week 60
The primary objective is to demonstrate that bexagliflozin is non-inferior to glimepiride by evaluating the treatment effect on HbA1c reduction at week 60 in subjects whose T2DM is inadequately controlled by metformin. The least square mean (LSM) change from baseline to Week 60 was analyzed using a mixed model repeated measures (MMRM) analysis of covariance model (ANCOVA).
Baseline and Week 60

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in Body Weight at Week 60 for Subjects With Baseline BMI ≥ 25 kg/m2
Time Frame: Baseline and 60 weeks
Least squares (LS) mean treatment difference between the bexagliflozin group and placebo group in the change of body weight in subjects with baseline BMI ≥ 25 kg/m2 at week 60 is analyzed using ANCOVA.
Baseline and 60 weeks
Change From Baseline in Systolic Blood Pressure (SBP) at Week 60 for Subjects With Baseline SBP ≥ 140 mmHg
Time Frame: Baseline and 60 weeks
Least squares (LS) mean treatment difference between the bexagliflozin group and placebo group in the change of SBP in subjects with baseline SBP ≥ 140 mmHg at week 60 is analyzed using ANCOVA.
Baseline and 60 weeks
Difference in Proportion of Subjects With ≥ 1 Severe or Documented Symptomatic Hypoglycemia Events Over 96 Weeks
Time Frame: During the 96 week treatment period
The difference in proportion of subjects with ≥ 1 severe or documented symptomatic hypoglycemia events in the bexagliflozin group compared with glimepiride group over 96 weeks is analyzed using a logistic regression model. The full model included region, baseline HbA1c value, background treatment status (metformin or metformin + OHA), eGFR at baseline ≥ 90 or < 90 mL min 1 per 1.73 m2), treatment as a fixed effect covariate.
During the 96 week treatment period
Superiority of Bexagliflozin Over Glimepiride in HbA1c Reduction at Week 60.
Time Frame: Baseline to Week 60
Superiority of bexagliflozin over glimepiride in HbA1c reduction from baseline to week 60 will be declared if the upper bound of 95% CI is less than 0.
Baseline to Week 60

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Theracos

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 15, 2016

Primary Completion (Actual)

June 14, 2019

Study Completion (Actual)

June 14, 2019

Study Registration Dates

First Submitted

May 3, 2016

First Submitted That Met QC Criteria

May 9, 2016

First Posted (Estimate)

May 11, 2016

Study Record Updates

Last Update Posted (Actual)

May 27, 2021

Last Update Submitted That Met QC Criteria

May 25, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • THR-1442-C-480

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 2 Diabetes Mellitus

Clinical Trials on Bexagliflozin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe